All In Biotech

Drug Trial Radar · NCT00710086

Intravenous Remifentanil for Labor Analgesia

Remifentanil Intravenous Patient-controlled Labor Analgesia for Nulliparous Women

Last checked: Nov 19, 2026Latest source record: Sep 18, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Jul 2008

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
Nanjing Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
HRSA/Maternal and Child Health Bureau
First posted
Jul 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Labor analgesia is an essential health caring procedure for women. However, epidural analgesia cannot be performed on all subjects for different contraindications, such as lower platelet counter, back infection at the puncture site, and fear of epidural injection etc. Therefore, intravenous analgesia is an alternative for such conditions. Given the influence of intravenous administration of drugs on fetus, the drug selection is very important. Remifentanil, a super-short efficacious opioid, can last for 3-4 minutes after injection, which is similar in both maternal and fetal environment. Thus the fetus-associated side effects would be less than other drugs. The investigators hypothesized that remifentanil would be a superior intravenous drug used with patient-controlled technique for labor analgesia.

Conditions

  • Labor Pain

Interventions

  • HydromorphoneDrug

    Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain

  • RemifentanilDrug

    Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maternal Visual Analog Scale (VAS) rating of painTime frame: Prior to analgesia, latent phrase, active phrase, second stage of labor, posterior to vaginal delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Maternal and Child Health Care Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.